Veeva Systems is overvalued, with modest ~10% growth & high valuation multiples. Read why I recommend a sell rating on VEEV ...

KeyBanc lowered the firm’s price target on Veeva (VEEV) to $250 from $260 and keeps an Overweight rating on the shares. Into Q1 earnings, the ...

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors ...

I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results ... Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition ...

A month has gone by since the last earnings report for Veeva Systems (VEEV). Shares have lost about 6.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Bug also noted that there is an increased emphasis on scientific dialogue between clinical experts and pharmaceutical companies, as this can drive therapy adoption. He quoted a Veeva survey of 100 ...

who’s senior manager of CRM events management strategy at Veeva. “Before COVID, pharma events were mainly face-to-face. There’s now a need to find different ways of interacting with HCPs.” ...

In a report released today, Saket Kalia from Barclays maintained a Buy rating on Veeva Systems (VEEV – Research Report), with a price target of $275.00. The company’s shares closed yesterday ...

A new pharma marketing content ebook from Veeva looks at best practices for building a content foundation that can enable long-term growth. It explains how to launch, scale faster, and improve the ...

In its fourth quarter 2024 investor letter, TimesSquare Capital Management U.S. Focus Growth Strategy emphasized stocks such as Veeva Systems Inc. (NYSE:VEEV). Veeva Systems Inc. (NYSE:VEEV ...

A Russian missile struck a warehouse belonging to Kusum Healthcare, an Indian pharmaceutical company, in Ukraine, prompting condemnation from the Ukrainian embassy, which alleged a deliberate ...